[go: up one dir, main page]

BRPI0915482B8 - derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, composições farmacêuticas e medicamentos compreendendo os mesmos - Google Patents

derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, composições farmacêuticas e medicamentos compreendendo os mesmos

Info

Publication number
BRPI0915482B8
BRPI0915482B8 BRPI0915482A BRPI0915482A BRPI0915482B8 BR PI0915482 B8 BRPI0915482 B8 BR PI0915482B8 BR PI0915482 A BRPI0915482 A BR PI0915482A BR PI0915482 A BRPI0915482 A BR PI0915482A BR PI0915482 B8 BRPI0915482 B8 BR PI0915482B8
Authority
BR
Brazil
Prior art keywords
piperazin
oxo
derivatives
alkyl
pharmaceutical compositions
Prior art date
Application number
BRPI0915482A
Other languages
English (en)
Inventor
Bono Françoise
Baroni Marco
Delbary-Gossart Sandrine
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0915482A2 publication Critical patent/BRPI0915482A2/pt
Publication of BRPI0915482B1 publication Critical patent/BRPI0915482B1/pt
Publication of BRPI0915482B8 publication Critical patent/BRPI0915482B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, e composições farmacêuticas e medicamentos compreendendo os mesmos. a presente invenção refere-se a derivados de derivados de 4-{2-[fenil-3,6- di-hidro-piridin-1- il]-2-oxo-alquil}-1- piperazin-2-ona e 4-{2-[fenil-2,5-di-hidro-pirrol -1-il} -2-oxo- alquil}-1-piperazin-2- ona de fórmula geral (i) em que a, b, m, r3 e n são definidos conforme na reivindicação 1, a respectiva preparação e a respectiva aplicação em terapêutica.
BRPI0915482A 2008-06-13 2009-06-12 derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, composições farmacêuticas e medicamentos compreendendo os mesmos BRPI0915482B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0803298A FR2932481B1 (fr) 2008-06-13 2008-06-13 Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR0803298 2008-06-13
PCT/FR2009/051117 WO2009150387A1 (fr) 2008-06-13 2009-06-12 Derives de 2-oxo-alkyl-1-piperazin-2-one, leur preparation et leur application en therapeutique

Publications (3)

Publication Number Publication Date
BRPI0915482A2 BRPI0915482A2 (pt) 2015-11-10
BRPI0915482B1 BRPI0915482B1 (pt) 2020-11-24
BRPI0915482B8 true BRPI0915482B8 (pt) 2021-05-25

Family

ID=40305319

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915482A BRPI0915482B8 (pt) 2008-06-13 2009-06-12 derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, composições farmacêuticas e medicamentos compreendendo os mesmos

Country Status (31)

Country Link
US (2) US8247404B2 (pt)
EP (1) EP2310383B8 (pt)
JP (1) JP5476372B2 (pt)
KR (1) KR101601999B1 (pt)
CN (1) CN102124001B (pt)
AR (1) AR072102A1 (pt)
AT (1) ATE535524T1 (pt)
AU (1) AU2009259120B2 (pt)
BR (1) BRPI0915482B8 (pt)
CA (1) CA2726666C (pt)
CL (1) CL2010001432A1 (pt)
CO (1) CO6300943A2 (pt)
CY (1) CY1112417T1 (pt)
DK (1) DK2310383T3 (pt)
EA (1) EA019924B1 (pt)
ES (1) ES2378380T3 (pt)
FR (1) FR2932481B1 (pt)
HR (1) HRP20120187T1 (pt)
IL (1) IL209903A (pt)
JO (1) JO2773B1 (pt)
MX (1) MX2010013694A (pt)
MY (1) MY151228A (pt)
NZ (1) NZ589842A (pt)
PL (1) PL2310383T3 (pt)
PT (1) PT2310383E (pt)
RS (1) RS52252B (pt)
SI (1) SI2310383T1 (pt)
TW (1) TWI400238B (pt)
UY (1) UY31894A (pt)
WO (1) WO2009150387A1 (pt)
ZA (1) ZA201008791B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP2950095B1 (en) 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) * 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
JP2003514508A (ja) * 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75

Also Published As

Publication number Publication date
US20110144122A1 (en) 2011-06-16
PT2310383E (pt) 2012-03-06
PL2310383T3 (pl) 2012-04-30
BRPI0915482B1 (pt) 2020-11-24
EA019924B1 (ru) 2014-07-30
ZA201008791B (en) 2012-02-29
IL209903A (en) 2014-06-30
UY31894A (es) 2010-01-29
HK1158632A1 (en) 2012-07-20
US8247404B2 (en) 2012-08-21
EA201170015A1 (ru) 2011-06-30
CY1112417T1 (el) 2015-12-09
CN102124001A (zh) 2011-07-13
EP2310383B8 (fr) 2012-04-11
JP2011522868A (ja) 2011-08-04
CA2726666A1 (fr) 2009-12-17
EP2310383A1 (fr) 2011-04-20
TW201002686A (en) 2010-01-16
CO6300943A2 (es) 2011-07-21
JO2773B1 (en) 2014-03-15
HRP20120187T1 (hr) 2012-03-31
IL209903A0 (en) 2011-02-28
KR101601999B1 (ko) 2016-03-17
EP2310383B1 (fr) 2011-11-30
JP5476372B2 (ja) 2014-04-23
MY151228A (en) 2014-04-30
SI2310383T1 (sl) 2012-03-30
CN102124001B (zh) 2014-01-22
ATE535524T1 (de) 2011-12-15
BRPI0915482A2 (pt) 2015-11-10
AU2009259120A1 (en) 2009-12-17
MX2010013694A (es) 2011-02-23
CA2726666C (fr) 2016-08-16
CL2010001432A1 (es) 2011-05-13
DK2310383T3 (da) 2012-03-26
RS52252B (en) 2012-10-31
AU2009259120B2 (en) 2014-01-16
US20120289518A1 (en) 2012-11-15
KR20110031317A (ko) 2011-03-25
AR072102A1 (es) 2010-08-04
NZ589842A (en) 2012-12-21
ES2378380T3 (es) 2012-04-11
FR2932481B1 (fr) 2010-10-08
TWI400238B (zh) 2013-07-01
WO2009150387A1 (fr) 2009-12-17
FR2932481A1 (fr) 2009-12-18

Similar Documents

Publication Publication Date Title
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BR112015020242A2 (pt) sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112015004205A2 (pt) sulfamoil-arilamidas e o uso das mesmas como medicamentos para o tratamento da hepatite b
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112013005622A2 (pt) heteroaril metil amidas
BRPI0510847A (pt) compostos inibidores de dpp-iv, sais farmaceuticamente aceitáveis e pró-fármacos dos mesmos, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
BRPI0717367B8 (pt) di-hidropirazolonas substituídas, seus usos e seu processo de preparação, e medicamento
CL2009001554A1 (es) Compuestos derivados de 4-(sulfonilaminoalquilamino)-n-fenil-n'-hidroxi-1,2,5-oxadiazol-3-carboximidamida; formas cristalinas; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades tales como cancer, infeccion viral, depresion, entre otras.
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112014012056A8 (pt) compostos farmacêuticos
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
BR112012007322A2 (pt) composto de 2-piridona usados como inibidores de neutrófilo elastase
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF